

<b>Form PTO-1449 Modified</b>		Docket No. <b>UPN-3832</b> (L-2091)		Serial No. <b>09/627,775</b>	
List of Patent and Publications Cited by Applicant (Use several sheets if necessary)		Applicant <b>Mark L. Greene, et al.</b>			
U.S. Department of Commerce Patent and Trademark Office		Filing Date <b>July 28, 2000</b>		Group <b>1646</b>	
<b>OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)</b>					
<b>Ac</b>	<b>AA</b>	Bucay, N., et al., "osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification," <i>Genes Dev.</i> , May 1, <b>1998</b> , 12(9), 1260-1268			
	<b>AB</b>	Kong, Y., et al., "OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis," <i>Nature</i> , January 28, <b>1999</b> , 397, 315-323			
	<b>AC</b>	Lacey, D.L., "Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation," <i>Cell</i> , April 17, <b>1998</b> , 93(2), 165-176			
	<b>AD</b>	McOsker, J.E., et al., "Preclinical pharmacology of risedronate, a third generation bisphosphonate," <i>J. Bone &amp; Mineral Research</i> , ISSN: 0884-0431, August 28-31, <b>1990</b> , page S105, No. 128, Abstract			
	<b>AE</b>	Mortensen, L., et al., "Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up," <i>J. Clinical Endocrinology and Metabolism</i> , February <b>1998</b> , 83(2), 396-402			
	<b>AF</b>	Shalhoub, V., et al., "Osteoprotegerin and osteoprotegerin ligand effects on osteoclast formation from human peripheral blood mononuclear cell precursors," <i>J. Cellular Biochem.</i> , February 1, <b>1999</b> , 72(2), 251-261			
	<b>AG</b>	Sietsema, W.K., et al., "Antiresorptive dose-responsere relationships across three generations of bisphosphonates," <i>Drugs Exptl. Clin. Res.</i> , <b>1989</b> , XV(9), 389-396			
	<b>AH</b>	Simonet, W.S., et al., "Osteoprotegerin: a novel secreted protein involved in the regulation of bone density," <i>Cell</i> , April 18, <b>1997</b> , 89(2), 309-319			
	<b>AI</b>	Singer, F.R., et al., "Risedronate, a highly effective oral agent in the treatment of patients with severe paget's disease," <i>J. Clinical Endocrinology and Metabolism</i> , June <b>1998</b> , 83(6), 1906-1910			
<b>Ac</b>	<b>AJ</b>	Siris, E.S., et al., "Risedronate in the treatment of paget's disease of bone: an open label, multicenter study," <i>J. Bone and Mineral Research</i> , June 6, <b>1998</b> , 13(6), 1032-1038			
<b>EXAMINER</b>		<i>Annu kr. Chakrabarti</i>		<b>DATE CONSIDERED</b> <i>1/10/02</i>	

## Form PTO-1449 Modified

Docket No.

UPN-3832

L-2091)

Serial No.

09/627,775

List of Patent and Publications  
Cited by Applicant  
(Use several sheets if necessary)

U.S. Department of Commerce  
Patent and Trademark Office

Applicant

Mark L. Greene, et al.

Filing Date

July 28, 2000

Group

1646

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AC	AK	Van Beek, E., "Dissociation of binding and antiresorptive properties of hydroxybisphosphonates by substitution of the hydroxyl with an amino group," <i>J. Bone and Mineral Research</i> , <b>1996</b> , 11(10), 1492-1497
	AL	Frattni, A. et al., "Defects in TCIRG1 subunit of the vacuolar proton pump are responsible for a subset of human autosomal recessive osteopetrosis", <i>Nature Genetics</i> , <b>1999</b> , 23, 447-451
	AM	Kornak, U. et al., "Loss of the CIC-7 chloride channel leads to osteopetrosis in mice and man", <i>Cell</i> , <b>2001</b> , 104, 205-215
	AN	Lacey, D.L. et al., "Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo", <i>Am. Jrl. Of Pathology</i> , <b>2000</b> , 157(2), 435-448
	AO	Li, Y.P. et al., "Atp6i-deficient mice exhibit severe osteopetrosis due to loss of osteoclast-mediated extracellular acidification", <i>Nature Genetics</i> , <b>1999</b> , 23, 447-451
	AP	Li, J. et al., "RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism", <i>PNAS</i> , <b>2000</b> , 97(4), 1566-1571
	AQ	Scimeca, J.C., "The gene encoding the mouse homologue of the human osteoclast-specific 116-kDa V-ATPase subunit bears a deletion in osteosclerotic (oc/oc) mutants", <i>Bone</i> , <b>2000</b> , 26(3), 207-213
	AR	Shalhoub, V. et al., "Characterization of osteoclast precursors in human blood", <i>British Jrl. Of Haematology</i> , <b>2000</b> , 111, 501-512
	AS	Weitzmann, M.N. et al., "T cell activation induces human osteoclast formation via receptor activator of nuclear factor k B ligand-dependent and -Independent mechanisms", <i>Jrl. of Bone and Mineral Research</i> , <b>2001</b> , 16(2), 328-337
AC		
EXAMINER	Aram kr. Chakrabarti	
	DATE CONSIDERED	1/10/02